Endocyte unveils final OS results from Phase 2b Target trial in NSCLC patients
The analysis focused on identifying small molecule drug conjugate (SMDC) vintafolide in combination with docetaxel in patients with FR positive recurrent NSCLC. Endocyte said vintafolide plus docetaxel enhanced